- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Rossari Biotech's Q1 FY26 revenue rose 11% YoY to Rs. 543.7 Cr. EBITDA hit Rs. 67.9 Cr (12.5% margin). Excluding the Institutional/B2C loss (Rs. 7 Cr), core EBITDA was Rs. 75 Cr (16% margin). Domestic business was robust, but exports softened due to global headwinds and Q1 plant shutdowns for capacity upgrades.
Management expects a stronger Q2. Capacity expansion projects are progressing well, poised to drive significant growth and 3-4x asset turnover from FY27. The institutional business targets EBITDA breakeven this fiscal. The company projects mid-double-digit revenue and EBITDA growth for FY26, emphasizing a confident outlook through strategic execution and enhanced capabilities.